Phase II trial of short-term neoadjuvant docetaxel and complete androgen blockade in high-risk prostate cancer.
Mellado B, Font A, Alcaraz A, Aparicio LA, Veiga FJ, Areal J, Gallardo E, Hannaoui N, Lorenzo JR, Sousa A, Fernandez PL, Gascon P.
Mellado B, et al. Among authors: font a.
Br J Cancer. 2009 Oct 20;101(8):1248-52. doi: 10.1038/sj.bjc.6605320. Epub 2009 Sep 15.
Br J Cancer. 2009.
PMID: 19755998
Free PMC article.
Clinical Trial.